Biotech Values

[DewDiligence]

BMY—I would say a settlement is possible, but not “likely.” The write-up you posted from SeekingAlpha is not exactly an authoritative source. It merely conveys that a Mizuho analyst said BMY “could” settle with former CELG shareholders using the Sanofi/Genzyme case as a template.